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A B S T R A C T
The success of disease-modifying osteoarthritis drug (DMOAD) development is still elusive. While there have
been successes in preclinical and early clinical studies, phase 3 clinical trials have failed so far and there is still
no approved, widely available DMOAD on the market. The latest research suggests that, among other causes,
poor trial outcomes might be explained by the fact that osteoarthritis (OA) is a heterogeneous disease with
distinct phenotypes. OA trials might be more successful if they would address and target a specific phenotype.
The increasing availability of advanced techniques to detect particular OA characteristics expands the pos-
sibilities to distinguish between such potential OA phenotypes. Magnetic resonance imaging is among the key
imaging techniques to stratify and monitor patients with changes in bone, cartilage and inflammation.
Biochemical markers have mainly used as secondary parameters and could further delineate phenotypes.
Moreover, post-hoc analyses of trial data have suggested the existence of distinct pain phenotypes and their
relevance in the design of clinical trials.
Although ongoing work in the field supports the concept of OA heterogeneity, this has not yet resulted in
more effective treatment options. This paper reviews the current knowledge about potential OA phenotypes and
suggests that combining patient clinical data, quantitative imaging, biochemical markers and utilizing data-
driven approaches in patient selection and efficacy assessment will allow for more successful development of
effective DMOADs.
1. Introduction
Conservative estimates state that up to 240 million people around
the world suffer from osteoarthritis (OA) [1]. On average, people begin
experiencing OA symptoms at the age of 55 years and live 26 years with
the symptoms [2,3]. OA decreases mobility, quality of life and pro-
ductivity and increases morbidity, use of healthcare services and social
expenditure [4]. Altogether, OA poses a large and very significant in-
dividual and societal burden [5]. Moreover, due to the ever-expanding
ageing population together with the increasing levels of sedentary be-
havior and the diminishing levels of physical activity that are fueling
the current obesity pandemic, the prevalence of chronic OA is expected
to increase further and become established as the most common form of
musculoskeletal disease by 2040.
Although the socioeconomic impact of OA is clear, existing ther-
apeutic options are very limited and what is available is modestly ef-
fective at best in most patients. Huge efforts have been put into de-
veloping more effective and/or disease modifying treatments.
Disease modifying OA treatments, by definition, are able to posi-
tively influence both the structural as well as symptomatic disease
course. A variety of potential disease modifying OA drugs (DMOADs)
have been suggested to be effective in preclinical and early clinical
studies but failed to reach structural and clinical endpoints in phase 3
clinical trials. A number of factors have been hypothesized to underlie
this disappointing outcome. One of them supposedly is that OA is a
heterogeneous disease, consisting of distinct subtypes, or phenotypes,
while preclinical OA models typically test a particular OA pathogenic
mechanism (e.g., mechanical instability, synovitis, or cartilage
https://doi.org/10.1016/j.bcp.2019.02.037
Received 14 January 2019; Accepted 28 February 2019
⁎ Corresponding author at: University Medical Center Utrecht, Department of Rheumatology & Clinical Immunology, PO Box 85500, 3508 GA Utrecht, The
Netherlands.
E-mail address: w.e.vanspil@umcutrecht.nl (W.E. Van Spil).
Biochemical Pharmacology 165 (2019) 41–48
Available online 01 March 2019




OA phenotypes can be defined as subtypes of OA that share distinct
underlying pathobiological and pain mechanisms and their structural
and functional consequences. As therapeutic interventions usually
target just one or a few disease mechanisms, they might not be equally
effective for all phenotypes. Consequently, any disease-modifying
ability of an intervention in subgroups of trial populations might be
diluted by the lack of efficacy in others. Also, representative outcome
measures for efficacy might be different between OA phenotypes. Thus,
the positive effect on radiographic joint space narrowing on standar-
dized joint radiographs, the current “gold standard” that is currently
required by regulatory agencies to qualify an agent as a DMOAD might
not suffice for all phenotypes.
When one or more OA phenotypes are validated, every OA patient
could be assessed for one or more parameters that characterize each of
these phenotypes. Patients could classify for one or more phenotypes at
the same time. This could help predict the future structural and/or
clinical disease course (i.e. prognosis) and define potentially effective
therapeutic targets in patients at high risk for disease progression.
Various imaging-based scoring systems and quantitative image as-
sessment methodologies have been used to study OA phenotypes, pri-
marily using conventional radiography or magnetic resonance imaging
(MRI) and to a lesser degree ultrasound, computed tomography (CT)
and nuclear medicine approaches that provide different means to
characterize both structural and compositional changes in different
joint tissues affected by OA. In trials, primarily radiography and/or MRI
are used to support patient selection and disease modification claims for
novel therapeutic agents. Fig. 1 illustrates examples of various imaging
techniques that are used in OA studies.
Also, biochemical and -omics markers (biomarkers) have been
proposed as phenotyping tools, although there are limited number of
studies published on the topic. Most biomarker studies are focused on
association with or correlation with disease stage or progression.
Nevertheless, biomarkers measured in blood or urine may provide in-
formation on disease activity through measures of inflammatory burden
(e.g. cytokine profiles), metabolic status (e.g. metabolomics), risk of
disease (e.g. genomics) and tissue health (e.g. extracellular matrix
turnover) [6,7].
The concept of OA heterogeneity and phenotypes is rapidly gaining
acceptance and a growing number of researchers, initiatives and studies
focus on or around this subject. In the current article, we will review
work that has been done in OA phenotyping and how this might impact
OA research and care. The focus will be on work that relates to or could
positively impact therapeutic innovation and the scope will be limited
to pharmacological interventions.
1.1. Conventional methods for phenotype definition
Most conventional methods for defining OA phenotypes distinguish
between the primarily or predominantly affected joint tissue(s), e.g.
articular cartilage, bone, osteophytes, bone marrow and/or synovial
tissue and/or distinguish between patients with and without a parti-
cular characteristic, such as an increased infrapatellar fat pad signal
intensity, high levels of a particular set of biochemical markers or a
decreased pain pressure threshold. The phenotypes that have more
symptoms and/or a worse prognosis (i.e. a need for treatment) may
offer a specific target for intervention and are the most interesting from
the therapeutic point of view.
1.1.1. Potential bone phenotypes
Although the general consensus is that bisphosphonates are in-
effective for reducing pain and structural progression in unselected
knee OA patients [8], bone marrow lesions (BMLs) on MRI have re-
ceived much interest over the last years, especially when testing new
molecules such as anti-interleukin-1 antibodies in synovitis-associated
OA and bisphosphonates [9].
BMLs appear as ill-defined signal intensity changes in the sub-
chondral bone that are hypointense on T1 weighed MR images and
hyperintense on fluid-sensitive images with fat saturation, i.e. T2
images, proton-weighted and fat-saturated images and/or short-TI in-
version recovery (STIR) images. Fig. 2 shows an advanced MRI se-
quence, known as dynamic contrast enhanced (DCE)-MRI, where
images are acquired over a period of 3–5min after the injection of a
gadolinium (Gd) based contrast agent. The images show the rate of Gd
absorption by soft tissues or tissue lesions, such as synovial tissue and
bone lesions. Once DCE-MRI is processed using specialist software
packages, a color overlay is displayed on grey-scale MRI, facilitating the
visual and quantitative assessment of the volume and severity of BMLs
and synovitis [10].
BMLs scored on static fluid-sensitive MRI sequences are positively
associated with symptoms and disease progression in knee OA [11,12].
They also suggest a phenotype of knee OA patients with particular in-
volvement of the subchondral bone in the disease process. Moreover,
this subchondral process might be amenable to agents that are readily
available from the osteoporosis field. Laslett et al. performed the
quintessential trial (ZAP1) on this subject by demonstrating that a
single gift of 5mg zoledronic acid in 59 patients with knee OA with
BMLs reduced the visual analogue score (VAS) for pain and areal BML
size at 6months as compared to placebo infusion [13]. The effects on
Fig. 1. Examples of various imaging technologies used in osteoarthritis (OA)
studies, using imaging results of a 57-year-old female with knee OA and a
painful and swollen knee. A) Conventional standing semiflexed radiograph of the
right knee, showing severe medial knee OA. B) Computed tomography (CT) scan of
the same knee, showing in more detail the kissing bone, osteophytes at the medial and
lateral joint margins and the tibial eminentia as well as subchondral sclerosis and
meniscal extrusion (arrow). C) 3D volume rendering of the CT scan, allowing to
study the bony morphology in 3D. It becomes apparent that osteophytes are made up
of a bony rim enlargement from the edges of both tibia and femur (arrows). D)
Coronal T1 weighted magnetic resonance imaging without fat saturation of the same
knee, now also showing small hypointense bone marrow lesions in the medial femur
and tibia (arrows).
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pain and BML size abated at 12months. After these encouraging results,
a multicenter, randomized, double-blind, placebo-controlled trial
(ZAP2) was performed to determine the effect of two annual infusions
of zoledronic acid on pain. This time also the cartilage volume was
measured at 24months in 223 knee OA patients with BMLs [14]. The
results of ZAP2 have so far been presented in abstract format only, but
were less promising than for ZAP1 [15]. It appeared that knee pain and
function and BML size at 24months in actively treated patients were
not statistically significantly different from patients that were ad-
ministered placebo. We note that the effects of zoledronic acid did seem
more prominent in a pre-specified subgroup of patients without radio-
graphic knee OA. The final and complete results of ZAP2 are eagerly
awaited and other trials of zoledronic acid or similar agents in knee OA
patients with BMLs are underway, including COAST-1 and ZODIAK
trials. Other bone-active agents might also be of interest in this respect.
A sub-analysis of the SEKOIA trial suggested that treatment with
strontium ranelate was able to reduce cartilage volume loss in patients
with knee OA with BMLs as compared to placebo [16]. Moreover, a
positive association between an increase in BML size and cartilage vo-
lume loss was observed in the placebo group, but not in patients that
were treated with strontium ranelate, 1 or 2 gr/day.
1.1.2. Potential inflammatory phenotypes
Synovitis, usually low-grade, is a common OA feature and could be
amenable to the wide range of anti-inflammatory agents that are
available for inflammatory rheumatic diseases. Commonly applied
imaging techniques for the identification and quantification of synovitis
are ultrasound (US) and MRI. MRI synovitis may manifest itself as a
thickened and contrast-enhancing synovial membrane and/or in-
directly as joint effusion and increased signal of a thickened synovium
on a fluid sensitive sequence (Fig. 3). When it comes to quantifying
synovitis, it is critical to use Gd based contrast agents as only the
contrast enhanced images differentiate effusion and synovium, thus
allowing for precise quantification of synovitis.
Hand OA, in particular the erosive form of hand OA is commonly
considered an inflammatory OA phenotype and seems to be an obvious
target for anti-inflammatory treatment. A number of anti-inflammatory
agents have been tested for efficacy in hand OA patients and US is a
Fig. 2. Magnetic resonance imaging (MRI) of bone marrow lesions (BMLs) in
knee osteoarthritis. These images were acquired from the same patient as in Fig. 1.
A) Proton density weighted MRI. Arrows point to the small ill-defined BMLs in femur
and tibia. Note the moderate effusion/synovitis in the suprapatellar pouch in the
upper part of the image. Most of the increased signal intensity corresponds to contrast
enhancing synovium in the suprapatellar pouch. B) 3D VIBE sequence with fat sa-
turation. Enhancement of the same BMLs in both femur and tibia with a similar size.
C) Dynamic contrast enhanced MRI. High perfusion in the same BMLs as in A and B.
However, in addition, there is a visible high enhancement of the subchondral bone in
both femur and tibia that is not visible on the static images in A and B.
Fig. 3. Magnetic resonance imaging (MRI) of synovitis and effusion in knee
osteoarthritis. These images were acquired from the same patient as in Figs. 1 and
2. A) Proton density weighted sagittal image through the mid-part of the knee,
showing moderate effusion/synovitis in the suprapatellar pouch in the upper part of
the image (*) as well as an increased signal intensity in Hoffa’s fat pad. B) Post
contrast gradient echo 3D VIBE sequence with fat saturation, showing increased
enhancement of an irregular thickened synovium of the suprapatellar pouch. Note the
hypointense area inside the enhancing synovium which corresponds to effusion, the
enhancing synovium on the inside of Hoffa’s fat pad and the slight enhancement in
the posterior capsule. C) Dynamic contrast enhanced MRI with the color map of the
initial rate of enhancement, the most severe inflammation is shown in white-bright
yellow and lower degrees of inflammation in red colors. The image shows spotted
areas of high perfusion in the synovial membrane in the suprapatellar pouch, high
uniform enhancement of the synovium covering Hoffa’s fat pad and slow enhance-
ment in the posterior capsule. This reflects different perfusion patterns of the various
tissues that could serve as specific inflammatory phenotype profiles.
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relatively inexpensive and accessible tool to detect inflammation in
these patients. Several recently published studies have found that US
based inflammatory signs in erosive hand OA [17–19] can predict
erosive progression [20]. The EHOA trial is a recently published one-
year, double-blind, randomised, placebo-controlled, multicenter trial in
90 patients with symptomatic, erosive and inflammatory hand OA [21].
Synovitis was assessed clinically and with US Power Doppler in all
patients and with MRI in a patient subset. Included patients were re-
quired to be non-responsive to a stable dose of non-steroidal anti-in-
flammatory agents. Etanercept® was dosed as 50mg/week for the first
24 weeks and as 25mg/week for the rest of the year. The visual ana-
logue scale (VAS) for pain and other clinical outcomes favored Eta-
nercept® over placebo, but differences were not statistically significant.
the trial showed that the joint ‘remodeling’ was higher in the Eta-
nercept® group and in joints with soft tissue swelling and/or power
Doppler signal in particular (i.e. positive statistical interaction). MRI
synovitis scores at one year did not differ between study arms, but BML
scores decreased more in the Etanercept® treated patients. Again, the
response was stronger in patients with MRI-detected synovitis.
The HUMOR trial followed a relatively similar approach and treated
43 symptomatic, erosive and inflammatory hand OA patients with
Adalimumab®, 40mg every other week, or placebo [22]. Synovitis was
assessed by MRI. No difference in pain was observed after 12 weeks.
Correspondingly, changes in synovitis and BML were small and similar
between study arms.
Synovitis is a feature of knee OA in substantial numbers of patients
and might even predate knee OA in some [23] (Fig. 3). It is associated
with pain and structural progression [23,24]. Lutikizumab® (ABT-981),
an anti–interleukin-1 alpha/beta dual variable domain im-
munoglobulin, was recently tested in a one-year, phase 2 trial in knee
OA patients with evidence of synovitis on ultrasound or MRI [25].
Lutikizumab® was administered subcutaneously, every other week, in
doses of either 25, 100, or 200mg. Lutikizumab® met the primary
endpoint of reduction in WOMAC pain at 16 weeks compared with
placebo at the dose of 100mg, but not at 25 mg or 200mg and not at
the other time points. Cartilage thickness, synovitis and other structural
endpoints both on MRI and radiographs were similar between Lutiki-
zumab® and placebo. Several biomarkers reflecting tissue inflammation
were measured in the two phase I studies, showing that these were
modulated in a dose-dependent way, indicating that select biomarkers
could reflect tissue inflammation complementary to imaging. Bio-
marker data from the phase II study have not been published.
One other interesting trial of intra-articular glucocorticoid injection
in 97 symptomatic hip OA patients quantified effusion-synovitis in the
index joint using ultrasound and MRI at baseline and 8weeks post-in-
jection [26]. The group as a whole showed clinical improvement in this
non-placebo-controlled study, but, surprisingly, baseline measures of
effusion-synovitis did not differ between responders and non-re-
sponders according to a variety of definitions. Although these data
might question the existence and/or relevance of an inflammatory hip
OA phenotype, it should be noted that none of the effusion-synovitis
measures changed from the injection. So, alternatively, this might in-
dicate that the measures for effusion-synovitis were not optimal for this
purpose.
1.1.3. Biochemical markers
Biochemical markers have the potential to add to the information
that can be obtained from imaging modalities, as they might serve as
dynamic measures of low-grade inflammation and/or metabolic al-
terations associated with some forms of OA. Biochemical markers in
blood and urine do, however, lack specificity for the index joint(s) and
are subject to multiple potential sources of background noise. Instead
biochemical markers may provide measures of disease activity on a
systemic level. It has been suggested that progression of disease hap-
pens in intervals, thus biochemical markers may be attractive for pa-
tient monitoring and for finding the timepoint where imaging
assessment should be conducted. In addition, one could imagine that
biochemical marker as monitoring tool could be used to identify turning
points and change in phenotypes during the course of disease devel-
opment; for example change from a phenotype without bone involve-
ment to a phenotype with bone involvement [27]. Biochemical markers
in synovial fluid are more specific for the index joint, but their mea-
surement is not standardized and requires relatively invasive ar-
throcentesis, which is often impractical from the perspective of clinical
trial design and patient retainment.
Some studies have attempted to distinguish between potential
phenotypes based on biochemical characteristics. One study assessed
high-sensitivity C-reactive protein, (hsCRP) and an MMP-derived de-
gradation fragment of C-reactive protein, CRPM, as a marker of more
chronic tissue inflammation in serum of primary knee OA patients.
They observed patients without increased hsCRP or CRPM levels (69%),
with only an increased hSCRP level (12%), with only an increased
CRPM level (13%), or with both increased hsCRP and CRPM levels
(6%). These subsets differed with regard to gender, body mass index,
radiographic knee OA severity and serum levels of MMP-derived
neoepitopes of collagen type 1, 2 and 3 (C1M, C2M and C3M, respec-
tively) [28]. Likewise, serum levels of C1M, C2M, C3M and CRPM and
erythrocyte sedimentation rate (ESR) were assessed in Cohort Hip &
Cohort Knee (CHECK), a cohort of persons with early-stage sympto-
matic primary knee and/or hip OA. Principal component analysis again
suggested that CRPM and C3M may reflect different inflammatory do-
mains than do hsCRP, ESR and C1M [29]. The potential relevance and
implications of these findings remain to be determined.
A recent study also illustrated that the driving inflammatory path-
ways in the OA process may differ between knee and hip. It appeared
that cytokines were differentially present in serum and synovial fluid
between knee and hip OA patients [30].
Biochemical markers have also been used as secondary outcome
parameters in OA trials. Although marker levels seem to be associated
with the efficacy of tested interventions in a number of studies, they do
not in others [31]. It is not always clear how such findings are to be
interpreted. In contrast, biochemical markers are obvious choice for
target engagement and pharmacodynamic markers. Such data may
provide link between the drug mode of action and efficacy, as well as
insight to the phenotypic differences between responding and non-re-
sponding patients. In other word, biochemical markers may through
DMOAD trials provide clue to the underlining mechanisms to different
phenotypes. Moreover, there is potential for combining imaging and
biochemical markers to develop combination markers.
1.1.4. Potential pain phenotypes
Pain phenotyping might also be relevant for DMOAD interventions,
as is illustrated by recent phase 2a and 2b trials of the Wnt pathway
inhibitor SM0460. In the phase 2a trial, 455 symptomatic and radio-
graphic knee OA patients were administered a single, intra-articular
injection of 0.03mg, 0.07mg, 0.23mg SM04690 or placebo [32]. Pain
and function improved at all time points in all study arms, including the
placebo arm, according to the Western Ontario and McMaster Uni-
versities Osteoarthritis Index (WOMAC) index. At 52 weeks, in a pre-
specified unilateral symptomatic subgroup, the 0.07mg dose group
showed significant improvements in WOMAC pain and clinically
meaningful and significant improvements in WOMAC function com-
pared to placebo. In a post-hoc subgroup with unilateral symptoms and
without widespread pain, the 0.07mg dose group showed both clini-
cally meaningful and significant improvements in WOMAC pain and
function compared to placebo at weeks 39 and 52, respectively.
Widespread pain was assessed by the Widespread Pain Index and
Symptom Severity Score. Radiographic joint space narrowing over
1 year as compared to placebo was decreased in the 0.07mg dose group
and in patients with unilateral symptoms only (with or without wide-
spread pain).
The phase 2b study included 695 knee OA patients with unilateral
W.E. Van Spil, et al. Biochemical Pharmacology 165 (2019) 41–48
44
symptoms only [33]. The results from this study confirmed the previous
finding that WOMAC and the numeric rating scale (NRS) for pain,
WOMAC physical function and patient global assessment were im-
proved at 12 and/or 24 weeks in the 0.07 and 0.23mg dose groups as
compared to placebo.
Interestingly, a post-hoc analysis of the placebo groups of two phase
3 trials of oral salmon calcitonin for knee OA showed that pain was
reduced more in the composite of questions related to weight-bearing
pain compared to non-weight-bearing pain of the target knee, sug-
gesting distinct categories of pain [34]. Likewise, one study suggests
that associations of inflammatory mediators might differ between pain
at rest and on movement [35].
Structural abnormalities and pain often correlate poorly. Imaging
findings and pain have been poorly linked in the past, especially when
using conventional radiographs that only show the late-stage bony
changes from OA and thus tells more about the patients OA history than
the current clinical status. Another big confounder for the missing link
between structural joint changes and pain is the inherent nature of OA
pain as remitting relapsing compared to the continuous slow progres-
sion of degenerative tissue changes with limited or no reversibility.
BMLs, synovitis and effusion are considered inflammatory markers and
have been linked to faster progression of both radiographic OA as well
as cartilage destruction on MRI. MRI detected synovitis can be seen in
more than 50% of patients with OA [36] and higher degrees of synovitis
is associated with more severe pain [24] as well as higher levels of
systemic and synovial pro-inflammatory cytokines [37,38]. This might
be the pain link as some of these cytokines (i.e IL-6) are known to
sensitize peripheral nerve-endings [39].
DCE-MRI has also been used to study synovitis and joint in-
flammation in knee OA, where high correlations between DCE-MRI
markers of increased perfusion and histological synovial biopsies were
found [40]. In addition, higher correlations between DCE-MRI markers
of perfusion and Knee injury and Osteoarthritis Outcome Score (KOOS)
pain scores have also been found in both the synovium [41] and Hoffa’s
fat pad [42] compared to conventional static MRI measures of synovitis
on both non-contrast and contrast enhanced MRI sequences, suggesting
that DCE-MRI might be the method of choice to find specific in-
flammatory phenotypes linked to specific cytokine profiles, histology,
pain severity and pain responses.
1.2. Novel methods and approaches for phenotype definition
The data above partly supports the plausible concept of OA phe-
notypes that might each require different approaches in terms of di-
agnosis, treatment and prognosis. Yet, they also illustrate that the
conventional methods for distinguishing between OA phenotypes might
not suffice for complex diseases such as OA. Novel approaches to dis-
tinguish between OA phenotypes and identify therapeutic targets for
these phenotypes are therefore of great interest and importance.
Synovial biopsies might also provide detailed information about the
nature of the synovitis in OA and/or inflammatory arthritis and syno-
vial biopsy could eventually be a useful tool in clinical trials [43,44].
One relatively small study showed increased expression of IL-17A in
synovial biopsies from knee or ankle joints of OA patients similar to that
in rheumatoid arthritis and psoriatic arthritis patients. Yet, it was also
observed that expression of IL-17A, IL-17F and their receptors was
highly variable between individual patients [45]. This might explain
why some patients do respond to IL17 inhibitors and others do not,
although this was not investigated in the current study. Although in-
formative from a research perspective, the invasive synovial biopsy is
unlikely to find its way to routine OA care anytime soon.
Imaging techniques that might also provide dynamic measures of
tissue composition and/or function or characteristics of present in-
flammation might be of particular interest for phenotyping OA patients.
Macrophages might play an important role in the synovitis in OA joints
and as such are potential therapeutic targets. The folate receptor β (FR-
β) is present on activated macrophages, but not on resting macrophages
or other immune cells. The FR-β can be targeted by the folate receptor-
specific molecular imaging agent etarfolatide (99mTc–EC20) for
SPECT/CT. It was shown that 76% of the 50 knees of 25 people with
radiographic and symptomatic OA in at least one knee were positive for
activated macrophages in at least one joint region, with uptake ob-
served in the joint capsule (immediately adjacent to the joint), syno-
vium and/or subchondral bone. Moreover, etarfolatide uptake was as-
sociated with pain severity and radiographic OA parameters.
Etarfolatide uptake was also observed in other joints, such as the finger
joints, thumb bases, shoulders, big toes and ankles, and was associated
with presence of pain in these joints as well [46]. To the best of our
knowledge, no interventional studies using etarfolatide imaging as an
outcome have been published so far.
There is increasing consensus that crystal deposition disease leading
to accelerated OA is underdiagnosed in OA trials as only the late
manifestations of the calcium pyrophosphate deposition disease and
gout can be appreciated on conventional radiographs and small calci-
fications can be invisible on MRI. Novel imaging technologies such as
dual energy CT and cone beam CT [47–49] with advanced dose re-
duction techniques can potentially aid in excluding crystal arthritis
patients from many OA trials as these patients are likely to have a
different pathogenesis.
Finally, continuous technological development of MRI might help
enrich certain phenotypes for OA studies or map both structural and
compositional changes in joint tissues. Fig. 4 gives examples of T2 MRI
maps for non-contrast cartilage composition and diffusion weighted
imaging and corresponding apparent diffusion coefficients (ADC) maps
for synovial and bone marrow inflammation that can complement the
static and dynamic perfusion MRI sequences.
“Omics” analysis of joint tissues such as cartilage, synovium and
synovial fluid using targeted approaches can be used to identify can-
didate biomarkers and potential therapeutic targets, thus underpinning
phenotyping and the development of future DMOADs [50]. However,
most “omics” analyses have focused on the associations of particular
molecules or molecular changes with OA presence, severity and rate of
progression so far, rather than on phenotype discovery. Moreover,
further integration with clinical and imaging data and validation stu-
dies has been advised to bring the “omics” field to its full potential and
translate its findings to useful tools in clinical care [51].
There has been a significant explosion in big data science in the last
decade. This development is revolutionizing the development of diag-
nostics and therapeutics, especially when combined with the afore-
mentioned high-throughput “omics” techniques. Applying computa-
tional approaches to “big data” from “omics” platforms can facilitate
the development of multiplex diagnostics for OA [52]. Comparative
proteomics of alkaptonuria, which can lead to an extreme form of OA
has already provided novel insights into inflammation and oxidative
stress by revealing pathologically elevated levels of CRP and advanced
oxidation protein products [53]. Including radio-omics with computer
assisted analysis of imaging data into this equation should help enhance
specific imaging phenotypes by i.e standardizing the analysis of joint
space narrowing and Kellgren & Lawrence or OARSI grading on con-
ventional radiographs [54], cartilage volume and thickness measure-
ments from MRI [55], meniscal tear evaluation [56], synovial volume
from static contrast enhancing MRI [57], synovial volume and perfu-
sion characteristics from DCE-MRI [10,57] and/or bone volume from
3D MRI [58,59] or CT scans [60] (Fig. 1).
2. Discussion
OA phenotyping has the potential to make important and impactful
contributions to the development of more effective and/or disease
modifying interventions for OA. Knowledge of heterogeneity of the
many aspects around OA would help refine the design of future trials of
potential DMOADs, better define potential treatment targets, improve
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the ability to select appropriate patients for the tested intervention and
to adapt outcome measures to the situation.
There is a need to effectively combine parameters that correspond to
different domains that might be relevant for OA phenotyping, including
measures for cartilage quality, three-dimensional bone morphology,
subchondral bone metabolism, inflammation and others into an inter-
pretable multi-parametric assessment. Ideally, these parameters are
easy and cheap to collect, also in clinical care. Nevertheless, in the
research stage, more specialized and/or complex methods might also be
useful to come to an OA phenotype classification.
Most current studies into OA phenotypes are focused around knee
OA [61]. OA driving mechanisms might, however, very well differ
between joints [30,62]. More research into other joints, such as the hips
and spine, is therefore to be encouraged.
Collaborations between different types of researchers in the OA field
will be particularly important for phenotype studies. To effectively
distinguish between phenotypes, data from different OA domains might
be needed (e.g. imaging, pain assessment, motion analyses, biochemical
markers, omics data) and researchers from each of these fields could
provide important knowledge and expertise. Moreover, some ap-
proaches will require complex statistical and computational analyses so
that statisticians, data scientists and computational scientists might
prove indispensable. Finally, the OA phenotype research field could
also benefit from knowledge that has been obtained from efforts to
phenotype other diseases.
Data on potential phenotypes might come from both preclinical and
clinical studies. Both observational (e.g., trajectory analyses) and in-
terventional studies (e.g., characterizing responders vs. non-responders
or studies in particular OA subtypes only) can be useful. Clinical studies
typically are, however, relatively expensive and organizationally com-
plex as compared to preclinical studies and this might be true all the
more for clinical studies to be of use for phenotype analyses. Typically,
they will then require more subjects and parameters to sufficiently
cover different phenotypes and/or longer follow-up times to distinguish
between trajectories or compare outcomes between phenotypes.
Combining basic patient information, functional imaging and carefully
selected panels of biochemical markers and omics data can help in
achieving enhanced patient stratification and lead to better designed
clinical trials [50] and enhance the ability to recruit the right patients
for trials [63].
3. Conclusion
The existing literature points to numerous clues that OA phenotypes
do actually exist. However, the OA phenotype research field is rela-
tively new and as an emerging area it has not yet matured or led to any
major discoveries with significant implications for the OA research field
and clinical care so far. It would appear that the hard work in this area
has yet to begin. Various international, US and EU based consortia have
focused on the use of clinical, imaging and biochemical data to study
disease progression in OA cohorts but very few studies have focused on
OA phenotypes. We need more high-quality and better standardized
data on the full spectrum of “omics” techniques and biochemical OA
markers and then link these data with sensitive imaging parameters
before we can develop combination biomarkers for different OA phe-
notypes. We need to assemble new panels of imaging and biochemical
markers that can distinguish between distinct OA phenotypes and this
can greatly facilitate drug development from early discovery to late
Fig. 4. Advanced MRI sequences and corresponding quantitative maps. Arrow points indicate the bone marrow lesion (BML) at all the different sequences. Top row,
from left to right: proton density weighted (PdW) sagittal image, T1 weighted gradient Echo VIBE post-contrast image, dynamic contrast enhanced (DCE) MR image
and the map of initial rate of enhancement (IRE), showing areas with more inflammation in white-yellow colors and the areas with less inflammation in red colors.
Bottom row, from left to right: diffusion weighted MRI, corresponding apparent diffusion coefficient (ADC) map allowing quantification of cellular density and water
diffusion, DCE-MRI with the map of maximum enhancement showing areas with much perfusion in white-yellow colors and areas of less perfusion in red colors, and
lastly, the T2 map showing cartilage composition. Note that the BML seen on the static and DCE-MRI sequences is not depicted on the diffusion map. On the other
hand, the increased signals in the tibial plateau on the diffusion weighted sequence and the ADC maps reflect increased water diffusion, corresponding to a higher
degree of perfusion (yellow colors) on the DCE-MRI sequences which might indicate a specific BML phenotype. This warrants more research. Also note that the T2
image shows high T2 values around 90ms in the cartilage adjacent to areas of denuded cartilage (red colors), while the ROI in the posterior part of the femoral
condyle has near-normal values around 46ms.
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clinical development [6,7].This is going to be a very challenging but
exciting and rewarding area of research activity in the future and
should enable us to develop combination biomarkers that can be used
to define and differentiate distinct OA phenotypes.
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